Evidence mapPaperPMID 39613480Full record

SynthesisMovement disorders : official journal of the Movement Disorder Society2025

Digital Outcomes as Biomarkers of Disease Progression in Early Parkinson's Disease: A Systematic Review.

Pablo Rábano-Suárez, Natalia Del Campo, Isabelle Benatru, Caroline Moreau, Clément Desjardins, Álvaro Sánchez-Ferro, Margherita Fabbri

Abstract readSystematic Review
In one paragraph

Synthesis in Movement disorders : official journal of the Movement Disorder Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Walking as a Window to the Brain: Redefining Gait in Neurology.Medical sciences (Basel, Switzerland) · 2026
    Review
  8. Review
  9. Digital Technologies for Symptom Monitoring in Parkinson Disease.Current neurology and neuroscience reports · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Sensors in Multiple Sclerosis.Current neurology and neuroscience reports · 2025
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pablo Rábano-SuárezHospital Universitario 12 de Octubre, Madrid, Spain.
Natalia Del CampoDepartment of Neurosciences, Clinical Investigation Center CIC 1436, Parkinson Toulouse Expert Centre, NS-Park/FCRIN Network and NeuroToul COEN Center, Toulouse University Hospital, INSERM, University of Toulouse 3, Toulouse, France.
Isabelle BenatruDepartment of Neurology, University Hospital of Poitiers, Poitiers, France.
Caroline MoreauDepartment of Neurology, LICEND COEN Center, Lille Neuroscience and Cognition, INSERM UMR S1172, CHU Lille, University Lille, Lille, France.
Clément DesjardinsDepartment of Neurology, Rothschild Foundation Hospital, Paris, France.
Álvaro Sánchez-FerroCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Margherita FabbriDepartment of Neurosciences, Clinical Investigation Center CIC 1436, Parkinson Toulouse Expert Centre, NS-Park/FCRIN Network and NeuroToul COEN Center, Toulouse University Hospital, INSERM, University of Toulouse 3, Toulouse, France.ORCID https://orcid.org/0000-0001-7250-592X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Outcomes derived from digital health technologies (DHTs) are promising candidate markers for monitoring Parkinson's disease (PD) progression. They have the potential to represent a significant shift in clinical research and therapeutic development in PD. However, their ability to track disease progression is yet to be established. This systematic review aimed to identify digital biomarkers capable of tracking early PD progression (disease duration <5 years) by reviewing longitudinal studies (minimum follow-up of 6 months). We evaluated study design and quality, population features, reported DHTs and their performance to track progression. Of 1507 records screened, 15 studies were selected, published between 2009 and 2023, with the majority coming from the last 5 years. Of the 15, 11 were observational and four were interventional trials (follow-up range: 6-60 months). Twelve different DHTs were used (8 required active tests, 8 in-hospital use), capturing features related to motor function and daily activities, including five DHTs focused on gait/posture. Rating scales were used as comparators in all but one study. Three DHTs detected longitudinal changes when scales did not, with one study showing larger effect sizes for change over time of selected DHT features compared to rating scales. Four studies showed longitudinal correlations among DHT features and rating scales. Preliminary promising data suggest that DHT-derived outcomes may help reduce sample sizes in disease-modifying trials. There is a need to standardize study methodologies and facilitate data sharing to confirm these results and further validate the sensitivity of DHTs to track disease progression in PD. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

Disease ProgressionParkinson DiseaseBiomarkersHumansBiomarkersclinical trialsdigital health technologydisease progressionearly stageParkinson's disease

Identifiers

PMID39613480
PMCPMC11832816

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.